|
Clonal evolution and drug resistance in the blood of patients with metastatic solid tumors responding to targeted therapies: The CORNUCOPIA study. |
|
|
Stock and Other Ownership Interests - Horizon Discovery |
Consulting or Advisory Role - Biocartis; Horizon Discovery; Trovagene |
Speakers' Bureau - Novartis |
|
|
Speakers' Bureau - AstraZeneca; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Travel, Accommodations, Expenses - Baxalta |
|
|
|
Research Funding - Celgene (Inst) |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; MSD Oncology; Novartis; SERVIER |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Lilly; Roche |
|
Travel, Accommodations, Expenses - Amgen; Bayer; Merck Serono; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Celgene; Novartis; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen; Bayer; Lilly; Merck; Roche; Sanofi |
|
|
|
Research Funding - Celgene (Inst) |